Pulse Biosciences (PLSE) EBITDA Margin (2021 - 2026)

Pulse Biosciences (PLSE) posted quarterly EBITDA Margin of 23682.56% for Q3 2025, down 347.83% quarter-over-quarter from 5288.3% in Q2 2022.

Pulse Biosciences (PLSE) EBITDA Margin (2021 - 2026) Analysis & Trends

Pulse Biosciences' EBITDA Margin history runs 3 years deep, the most recent figure standing at 23682.56% for Q3 2025.

In Q3 2025, EBITDA Margin changed N/A year-over-year to 23682.56%; the TTM figure through Sep 2025 stood at 91798.84% (changed N/A YoY), while the FY2022 annual figure was 8293.86%, down 379286.0% from the prior year.
EBITDA Margin for Q3 2025 stood at 23682.56%, down from 5288.3% in the prior quarter.
The five-year high for EBITDA Margin was 1865.62% in Q4 2021, with the low at 23682.56% in Q3 2025.
The 3-year median for EBITDA Margin is 3890.32% (2022), against an average of 7442.68%.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Intuitive Surgical	134.99 Bn	129.78 Bn	1.96 Bn	33.60%
2	Becton Dickinson	52.55 Bn	51.69 Bn	2.32 Bn	13.31%
3	Alcon	35.75 Bn	34.39 Bn	1.68 Bn	0.39%
4	Resmed	34.00 Bn	32.53 Bn	861.22 Mn	30.66%
5	Medline	29.09 Bn	26.41 Bn	2.22 Bn	5.14%
6	West Pharmaceutical Services	24.85 Bn	24.42 Bn	329.20 Mn	20.53%
7	Solventum	15.30 Bn	14.89 Bn	1.29 Bn	8.19%
8	Cooper Companies	14.86 Bn	14.72 Bn	735.40 Mn	-2.87%
9	Baxter International	13.63 Bn	11.48 Bn	1.03 Bn	7.33%
10	Pulse Biosciences	3.42 Bn	3.42 Bn	161,000.00	-5,823.04%

Download Data